CPT code 17286: Destruction of malignant skin lesions on the face

Key takeaways

CPT code 17286 covers destruction of a malignant lesion over 4.0 cm on the face, ears, eyelids, nose, lips, or mucous membranes.

Code selection depends only on anatomic location and the lesion’s own diameter, never on the destruction method used.

Missing pathology confirmation of malignancy and incorrect lesion size measurement are the two most common denial triggers for CPT 17286 claims.

Practice management software like Pabau helps dermatology practices track documentation requirements and reduce CPT 17286 billing errors.

CPT code 17286 covers destruction of a malignant lesion on the face, ears, eyelids, nose, lips, or mucous membranes. The lesion itself must measure over 4.0 cm in diameter. Dermatology coders working with this code must confirm two things before submission. The anatomic site must fall within the listed locations, and the lesion’s own diameter must clear the 4.0 cm threshold. Both conditions must be documented.

The American Medical Association (AMA) maintains the CPT code set, which places 17286 in the integumentary system section, within the destruction of malignant lesions subsection. The AMA long descriptor reads: “Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membranes; over 4.0 cm.” Dermatology practices handling dermatology EMR software workflows will encounter this code most often for advanced basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Both commonly appear in the head and neck region.

The key parameters for correct use are:

• Anatomic location: Face, ears, eyelids, nose, lips, or mucous membranes only
• Lesion diameter: Greater than 4.0 cm (not equal to 4.0 cm), measured as the lesion’s own size – never a margin-inclusive figure
• Lesion type: Malignant – confirmed by pathology or biopsy before or at the time of procedure
• Destruction method: Any of the five named modalities (see accepted methods section below)

CPT 17286 in the 17260-17286 destruction series

CPT Code 17286 sits at the top of the 17260-17286 series, which covers all malignant lesion destruction by anatomic site and lesion size. Understanding where 17286 falls in this series prevents upcoding and downcoding errors. The 17280-17286 subseries is specific to face, ears, eyelids, nose, lips, and mucous membranes. The parallel code for trunk, arms, or legs at the same size threshold is CPT 17264. Coders researching other CPT procedure codes across specialties will find the same size-threshold logic applied throughout the integumentary section.

Note that the scalp and neck are NOT included in the 17280-17286 series despite some third-party references suggesting otherwise. For the scalp, neck, hands, feet, and genitalia within the same size range, see CPT 17274 instead. Verify the anatomic site against the AMA long descriptor before submitting.

How to measure the lesion for code selection

Incorrect lesion measurement is one of the most common triggers for CPT 17286 audit findings. The measurement used for code selection is the lesion’s own diameter, its greatest dimension. It is not a measurement that adds surgical margins on top of the lesion.

This is where destruction codes differ from excision codes. The excision series for malignant lesions (11600-11646) sizes the wound differently. It adds the lesion’s diameter to twice the narrowest margin needed to remove it, because excision takes a wider circle of tissue with it. Destruction codes 17260-17286 don’t work that way. The code is selected on the lesion’s own diameter, regardless of how much surrounding tissue the destruction technique also affects.

For electrodesiccation and curettage (ED&C), measure after curettage but before electrodesiccation. Curettage often reveals that the malignancy extends beyond the visible clinical border. The post-curettage measurement can exceed the initial clinical estimate as a result. That post-curettage figure, not the original estimate, determines the code. Margins added afterward by electrodesiccation to destroy any remaining malignant cells play no part in the measurement.

For example, a facial basal cell carcinoma measures 3.8 cm at clinical presentation. During ED&C, curettage extends the visible malignant tissue to a diameter of 4.3 cm before electrodesiccation is applied. Code selection is based on that 4.3 cm post-curettage measurement, so 17286 is correct. The initial 3.8 cm clinical estimate would have pointed to 17284 instead. The final defect size after electrodesiccation is irrelevant to code selection.

• Measure the lesion’s own diameter, never the post-treatment defect
• For ED&C, measure after curettage but before electrodesiccation
• Record in centimeters to one decimal place (e.g., 4.3 cm)
• For irregular lesions, measure the greatest dimension
• Do not use the pathology specimen size as a substitute – tissue contracts after removal

Practices that use full-body mole mapping workflows have a documentation advantage here. Systematic measurement tracking at each encounter means the pre-procedure baseline size is already on file. That record supports the medical necessity narrative when a lesion has grown enough to warrant destruction.

Accepted methods of destruction

The CPT descriptor for 17286 names five accepted destruction modalities. The critical rule: the method used does NOT determine the code. Size and location are the only selection factors.

Mohs surgery note: When a procedure uses Mohs micrographic surgery technique with intraoperative margin control and pathology evaluation, use CPT codes 17311-17315 instead. The 17286 destruction series does not include the pathology interpretation component that defines Mohs surgery.

Documentation requirements for CPT code 17286

CMS and most commercial payers require specific documentation before a CPT Code 17286 claim will process without review. Missing any of these elements is the fastest path to a denial or audit request. Practices using digital intake forms and structured clinical notes can build these checkpoints directly into the pre-procedure workflow.

• Malignancy confirmation: Pathology or biopsy report confirming the lesion is malignant. Some Medicare Administrative Contractor (MAC) jurisdictions require this before the procedure; verify your local LCD.
• Anatomic site specificity: The exact location must be documented (e.g., “left nasal ala,” not just “nose”). Vague site documentation is a denial trigger.
• Lesion diameter: The lesion’s own diameter – never a margin-inclusive figure – recorded in centimeters. For ED&C, this is the post-curettage, pre-electrodesiccation measurement. It must match the submitted code threshold (greater than 4.0 cm for 17286).
• Destruction method: Name the specific method used (e.g., “electrodesiccation and curettage”). This does not change the code but is required for complete operative documentation.
• Medical necessity narrative: Brief statement explaining why destruction was selected over excision, or confirming patient is not a Mohs candidate. This is especially important for lesions where Mohs would be the typical treatment choice.
• Physician attestation: The treating physician’s signature and credentials, confirming they performed or directly supervised the procedure.

ICD-10-CM codes paired with CPT code 17286

Every CPT Code 17286 claim requires a supporting ICD-10-CM diagnosis code confirming malignancy. Payers cross-reference the procedure code against the diagnosis to validate medical necessity. The ICD-10-CM codes most commonly paired with 17286 break down by tumor type and anatomic sub-site. For more on how anatomic sub-site coding applies elsewhere, ICD-10 code L45 shows the same specificity requirement for a different skin diagnosis.

Verify each ICD-10-CM code against the current CMS code set before submitting. Codes are updated annually each October 1, and a code valid in one fiscal year may be retired or revised in the next. The AAPC Codify lookup tool includes ICD-10 crosswalk data that can confirm current pairings.

Medicare reimbursement and RVUs for CPT 17286

Medicare reimbursement for CPT 17286 is calculated from the Relative Value Units (RVUs) assigned to the code. That figure is multiplied by the geographic practice cost index (GPCI) for the practice location and the current conversion factor. The CMS Physician Fee Schedule provides the authoritative rates by locality and year. Always verify current rates there rather than relying on third-party figures.

For current RVU values, use the FastRVU 2026 lookup tool, which draws from CMS data and allows filtering by locality. Payment rates vary by MAC jurisdiction and change with each annual Medicare Physician Fee Schedule update. Practices in high-cost metropolitan areas typically receive higher locality-adjusted payments than the national average.

Modifiers commonly used with CPT code 17286

Modifier selection for CPT Code 17286 depends on the clinical scenario. Applying the wrong modifier, or omitting a required one, is a frequent cause of claim rejection. Practices managing multiple-code dermatology claims can benefit from structured claims management workflows that flag modifier requirements automatically.

CPT 17286 vs CPT 17284: Choosing the right code

CPT 17284 and CPT 17286 are the two highest-tier codes in the face/ear/nose/lips/mucous membranes destruction series. They share the same anatomic locations and the same accepted destruction methods. The only difference is the lesion diameter threshold. Selecting between them comes down to a single measurement, which makes accurate documentation of the lesion’s own diameter critical for every claim in this category.

When a measured lesion diameter sits exactly at 4.0 cm, use CPT 17284. Code 17286 requires the diameter to exceed 4.0 cm. Documenting a borderline measurement as “approximately 4 cm” creates ambiguity that an auditor will resolve in the payer’s favor. Measure precisely and document the exact figure. Dermatology practice teams can review how consistent measurement documentation supports compliance across a broader set of procedures in Pabau’s skin clinic software workflows.

Billing multiple lesions on the same date of service

Dermatology practices frequently treat multiple malignant lesions in a single session. Billing more than one destruction code on the same date requires following National Correct Coding Initiative (NCCI) guidelines. Applying these rules incorrectly is a common source of claim rejections and post-payment audits.

The core rule: each separately treated lesion may be billed with its appropriate code from the 17260-17286 series. Each lesion must meet the code’s anatomic and size criteria independently. When two codes within the series are billed together and an NCCI edit pairs them, modifier -59 is required. It indicates each service is a distinct procedural service at a different anatomic site.

• Each lesion must be documented separately in the operative note with its own site description and lesion diameter
• Do not add lesion sizes together to reach a higher-tier code – each lesion is coded independently
• Modifier -59 is required when billing codes that have an NCCI bundling relationship on the same date
• Verify current NCCI edit pairs before submitting multi-code claims – edits are updated quarterly
• Some MACs may require separate line items per lesion even when the same code is billed twice

Billing specialists who also code other procedure types can compare same-date service rules across specialties. The ADHD screening CPT code shows how these rules apply in a different clinical context.

Common billing errors and denial reasons

Most CPT 17286 denials stem from the same small set of documentation and coding errors. Identifying these patterns in advance is far more efficient than working appeals after the fact. Structured medical documentation practices at the point of care catch the majority of these errors before submission.

How Pabau supports accurate CPT 17286 documentation

Many dermatology practices track pathology reports, lesion measurements, and modifier rules across a paper chart, a spreadsheet, and an EHR. None of those systems talks to the practice management platform that actually files the claim.

Pabau keeps intake forms, clinical notes, and claims in one record. A digital intake form captures the pathology confirmation and exact anatomic site at check-in. The claims management software then flags a missing lesion diameter or an absent modifier before the claim goes out.

The result is fewer claims returned for missing pathology reports or vague measurements, and faster reimbursement on multi-lesion, same-date visits.

Streamline dermatology billing with Pabau

Pabau's claims management software helps dermatology practices track CPT documentation requirements, reduce billing errors, and manage multi-code claims on the same date of service.

Book a demo

Conclusion

CPT 17286 claims succeed or fail on three details. Each must be captured before the patient leaves the room: pathology confirmation, the lesion’s own diameter, and the anatomic sub-site. Reconstructing any of these after the fact is unreliable and slows every claim behind it.

Practices that build these checks into the visit itself submit cleaner claims than those that reconstruct documentation later. That matters most on high-value destruction codes like 17286, where a single missing detail can trigger a denial. Book a demo to see how Pabau supports dermatology billing from intake through claim submission.

Continue your research

Managing a multi-location dermatology practice? Skin clinic software features covers how Pabau supports clinical workflows, documentation, and compliance across skin-focused practices.

Want to understand billing compliance requirements more broadly? Med spa compliance workflows outlines the documentation and billing compliance standards that apply across aesthetic and dermatology practice types.

Coding destruction of a vascular skin lesion instead? CPT code 17108 covers the size-based rules for cutaneous vascular proliferative lesions.

Frequently asked questions